POTENT INHIBITION OF TERMINAL COMPLEMENT ASSEMBLY BY CLUSTERIN - CHARACTERIZATION OF ITS IMPACT ON C9 POLYMERIZATION

Citation
Jf. Mcdonald et Gl. Nelsestuen, POTENT INHIBITION OF TERMINAL COMPLEMENT ASSEMBLY BY CLUSTERIN - CHARACTERIZATION OF ITS IMPACT ON C9 POLYMERIZATION, Biochemistry, 36(24), 1997, pp. 7464-7473
Citations number
43
Categorie Soggetti
Biology
Journal title
ISSN journal
00062960
Volume
36
Issue
24
Year of publication
1997
Pages
7464 - 7473
Database
ISI
SICI code
0006-2960(1997)36:24<7464:PIOTCA>2.0.ZU;2-G
Abstract
The interactions of the heterodimeric apolipoprotein and complement in hibitor, clusterin (CL, 80 kDa), with actively assembling terminal com plement proteins were characterized. Clusterin inhibited at three site s and by two modes of action. Clusterin inhibited C9 assembly on C5b-8 and C5b-9 and also bound to C5b-7 to prevent membrane attachment. The impact on C5b-9 assembly was the most potent. C9 assembly was monitor ed by assembly-induced fluorescence changes of C9 labeled with fluores cein isothiocyanate (FITC-C9). Assembly of monomeric FITC-C9 with C5b- 8 or C5b-9(1) produced a substantial decrease in fluorescence intensit y due to changes in the environment of the probe. Addition of the next subunit of unlabeled C9 produced a further small change. One equivale nt of FITC-CB bound to C5b-8 at low temperatures, but the fluorescence change and addition of more C9 did not occur until the temperature wa s increased. Kinetic analysis of the fluorescence change suggested an irreversible, first-order process with an activation energy of 29 kcal /mol (k = 0.12 s(-1) at 25 degrees C). The kinetic properties differed for C9 addition to C5b-9(1) (0.27 s(-1) at 25 degrees C, 21 kcal/mol) , indicating that Cg activation occurred at a different or altered sit e. Clusterin binding to C5b-8-(FITC-C9)(1) caused fluorescence quenchi ng similar to that of unlabeled C9, indicating that it bound to the C9 binding site, Clusterin binding to C5b-8 and C5b-9(1) was reversible with affinities that were 2 and 15 times that of C9 for the C5b-8 and C5b-9(1) complexes, respectively. The results suggested that the prese nce of <10% of the circulating clusterin in its heterodimeric, active form could reduce the rate of complement cytolysis of nucleated cells by 10-fold, and under some conditions by 100-fold or more. This would provide a high level of protection for certain cells and may allow tim e for action by other inhibitors of complement.